catalyst
biosciences
participate
two
upcoming
investor
conferences
south
san
francisco
globe
newswire
catalyst
biosciences
nasdaq
cbio
today
announced
nassim
usman
president
chief
executive
officer
clinton
musil
chief
financial
officer
catalyst
biosciences
participate
fireside
chats
two
investor
conferences
september
morgan
stanley
global
healthcare
conference
cantor
virtual
global
healthcare
conference
details
found
morgan
stanley
global
healthcare
conference
date
thursday
september
time
pm
eastern
time
webcast
webcast
cantor
virtual
global
healthcare
conference
date
thursday
september
time
pm
eastern
time
webcast
cantor
webcast
archived
webcast
presentations
available
days
events
presentations
page
investors
section
company
website
catalyst
biosciences
catalyst
research
clinical
development
biopharmaceutical
company
focused
addressing
unmet
needs
rare
hematologic
disorders
protease
engineering
platform
includes
two
clinical
programs
hemophilia
research
program
engineering
subcutaneous
sq
complement
inhibitors
partnered
preclinical
development
program
biogen
dry
macular
degeneration
amd
product
candidates
generated
protease
engineering
platform
improved
functionality
potency
allow
sq
administration
recombinant
coagulation
factors
complement
inhibitors
high
activity
gene
therapy
constructs
less
frequently
dosed
intravitreal
therapeutics
advanced
product
candidate
marzeptacog
alfa
activated
marzaa
sq
fviia
entering
phase
registration
study
late
next
product
candidate
dalcinonacog
alfa
dalca
sq
fix
demonstrated
efficacy
safety
phase
clinical
trial
individuals
hemophilia
b
discovery
stage
factor
ix
gene
therapy
construct
cb
hemophilia
b
demonstrated
superiority
compared
padua
variant
preclinical
models
finally
global
license
collaboration
agreement
biogen
development
commercialization
factor
pegylated
cb
statements
press
release
contains
statements
involve
substantial
risks
uncertainties
statements
include
statements
potential
benefits
products
based
catalyst
engineered
protease
platform
plans
enroll
first
patients
phase
registration
study
marzaa
late
potential
marzaa
dalca
effectively
therapeutically
treat
hemophilia
subcutaneously
superiority
cb
gene
therapy
development
factor
pegylated
cb
biogen
actual
results
events
could
differ
materially
plans
intentions
expectations
projections
disclosed
statements
various
important
factors
could
cause
actual
results
events
differ
materially
including
limited
risk
trials
studies
may
delayed
result
pandemic
factors
trials
may
satisfactory
outcomes
additional
human
trials
replicate
results
earlier
trials
potential
adverse
effects
may
arise
testing
use
dalca
marzaa
including
generation
neutralizing
antibodies
observed
patients
treated
dalca
risk
costs
required
develop
manufacture
company
products
higher
anticipated
including
result
delays
development
manufacturing
resulting
factors
risk
biogen
terminate
catalyst
agreement
competition
risks
described
risk
factors
section
company
quarterly
report
filed
securities
exchange
commission
august
filings
securities
exchange
commission
company
assume
obligation
update
statements
except
required
law
contact
ana
kapor
catalyst
biosciences
investors
